View More Recent Stories

Jan 4, 2025 04:00PM 2025 Biopharma sector outlook
Jan 2, 2025 01:02PM Piper Sandler Highlights NBIX, ITCI, ALKS, AXSM as High Conviction Ideas in Biotechnology
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Dec 23, 2024 09:52AM Piper Sandler Reiterates Overweight Rating on Neurocrine Bio. (NBIX) After the Commercial Llaunch of Crinecerfont
Dec 22, 2024 04:00AM Barclays shares outlook for Biotech in 2025, names preferred stocks
Dec 20, 2024 12:49PM Neurocrine Bio. (NBIX) PT Raised to $182 at BofA Securities
Dec 20, 2024 08:02AM Neurocrine Biosciences (NBIX) Announces Commercial Availability of CRENESSITY for Children and Adults With Classic Congenital Adrenal Hyperplasia
Dec 19, 2024 11:16AM RBC Capital's Game Changers: 'Disruptive Forces in Biotech'
Dec 16, 2024 11:09AM Neurocrine Biosciences (NBIX) Announces FDA Approval of CRENESSITY (earlier)
Dec 16, 2024 06:52AM H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Dec 16, 2024 06:48AM Neurocrine Bio. (NBIX) PT Raised to $182 at Goldman Sachs
Dec 16, 2024 04:20AM BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX)
Nov 14, 2024 07:07AM Piper Sandler Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
Nov 4, 2024 08:25AM Neurocrine Biosciences (NBIX) Presents New Data on INGREZZA Capsules
Oct 31, 2024 08:39AM Neurocrine Bio. (NBIX) PT Raised to $121 at BMO Capital
Oct 30, 2024 07:03AM Neurocrine Biosciences (NBIX) Tops Q3 EPS by 29c, Beats on Revenue; Offers FY24 Revenue Guidance
Oct 22, 2024 06:10AM Oppenheimer Reiterates Outperform Rating on Neurocrine Bio. (NBIX)
Oct 14, 2024 07:28AM Piper Sandler Reiterates Overweight Rating on Neurocrine Bio. (NBIX)
Oct 10, 2024 08:21AM Raymond James Resumes Neurocrine Bio. (NBIX) at Outperform
Oct 8, 2024 06:32AM RBC Capital Reiterates Sector Perform Rating on Neurocrine Bio. (NBIX)
Sep 30, 2024 08:31AM Neurocrine Biosciences (NBIX) Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Sep 27, 2024 06:41AM Mizuho Reiterates Neutral Rating on Neurocrine Bio. (NBIX)
Sep 13, 2024 08:56AM BMO Capital Reiterates Market Perform Rating on Neurocrine Bio. (NBIX)
Sep 12, 2024 04:05PM Neurocrine Biosciences (NBIX) Provides Update on ERUDITE Phase 2 Data for Luvadaxistat
Aug 29, 2024 08:15AM H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Aug 29, 2024 03:02AM Piper Sandler Upgrades Neurocrine Bio. (NBIX) to Overweight
Aug 28, 2024 04:16PM Neurocrine Bio. (NBIX) PT Lowered to $128 at BMO Capital
Aug 28, 2024 12:13PM TD Cowen Reiterates Buy Rating on Neurocrine Bio. (NBIX)
Aug 28, 2024 07:42AM Neurocrine shares slump on Phase 2 results for schizophrenia treatment
Aug 28, 2024 07:00AM Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1117568
Aug 19, 2024 05:37AM Neurocrine Bio. (NBIX) PT Raised to $189 at Jefferies
Aug 2, 2024 06:48AM Neurocrine Bio. (NBIX) PT Raised to $190 at H.C. Wainwright
Aug 1, 2024 03:55PM Neurocrine Bio. (NBIX) PT Raised to $158 at Citi
Aug 1, 2024 07:09AM Neurocrine Biosciences (NBIX) Tops Q2 EPS by 50c
Jul 18, 2024 08:38AM Neurocrine Biosciences (NBIX) Launches INGREZZA SPRINKLE Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing
Jul 1, 2024 07:30AM Neurocrine Biosciences (NBIX) Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH
View More Recent Stories